ChiCTR2000039631 版本V1.6 版本创建时间2021/02/08 01:00:38 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000039631 

最近更新日期:

Date of Last Refreshed on:

2021-02-08 00:59:55 

注册时间:

Date of Registration:

2020-11-03 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

电针联合tACS对轻度认知障碍患者的工作记忆及执行功能的疗效观察及机制研究

Public title:

Effect of electroacupuncture combined with tACS on working memory and executive function in patients with mild cognitive impairment and its mechanism

注册题目简写:

English Acronym:

研究课题的正式科学名称:

电针联合tACS对轻度认知障碍患者的工作记忆及执行功能的疗效观察及机制研究

Scientific title:

Effect of electroacupuncture combined with tACS on working memory and executive function in patients with mild cognitive impairment and its mechanism

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李源莉 

研究负责人:

单春雷 

Applicant:

Yuanli Li 

Study leader:

Chunlei Shan 

申请注册联系人电话:

Applicant telephone:

+86 18717813558

研究负责人电话:

Study leader's
telephone:

+86 13816215058

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

Liyuan218@126.com

研究负责人电子邮件:

Study leader's E-mail:

534489132@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国上海虹口区甘河路110号

研究负责人通讯地址:

上海市浦东新区蔡伦路1200号10号楼10104室

Applicant address:

110 Ganhe Road, Hongkou District, Shanghai, China

Study leader's address:

Room 10104, Building 10, 1200 CaiLun Road, Pudong New Area, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海中医药大学

Applicant's institution:

Shanghai University of Traditional Chinese Medicine

研究负责人所在单位:

上海中医药大学

Affiliation of the Leader:

Shanghai University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2019-077

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海中医药大学附属岳阳中西医结合医院伦理委员会

Name of the ethic committee:

Ethics Committee in Yueyang Hospital of Integrated Traditional Chinese and Western Medicine affiliated to Shanghai University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2019-08-13 00:00:00

伦理委员会联系人:

殷从全

Contact Name of the ethic committee:

Congquan Yin

伦理委员会联系地址:

中国上海虹口区甘河路110号

Contact Address of the ethic committee:

110 Ganhe Road, Hongkou District, Shanghai, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海中医药大学附属岳阳中西医结合医院

Primary sponsor:

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine affiliated to Shanghai University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

中国上海虹口区甘河路110号

Primary sponsor's address:

110 Ganhe Road, Hongkou District, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海中医药大学附属岳阳中西医结合医院

具体地址:

虹口区甘河路110号

Institution
hospital:

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine affiliated to Shanghai University of Traditional Chinese Medicine

Address:

110 Ganhe Road, Hongkou District

经费或物资来源:

上海市卫生和计划生育委员会

Source(s) of funding:

Shanghai health and family planning commission

研究疾病:

轻度认知障碍  

Target disease:

Mild cognitive impairment

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

tACS联合EA对MCI患者的工作记忆及执行功能的疗效观察及机制探讨。  

Objectives of Study:

Effect of tACS combined with EA on working memory and executive function in PATIENTS with MCI and its mechanism.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.符合MCI的核心临床诊断标准;
2.年龄≥50周岁且≤85周岁,性别不限;
3.简易精神状态量表评分:文盲18~19 分,小学 21~22 分,中学及中学以上 25~27 分显示无异常;
4.蒙特利尔认知评估量表评分:低等教育(受教育年限≤12 年)19~25 分,高等教育(受教育年限>12 年)19~26分提示存在轻度异常。
5.临床痴呆评定量表评分≤ 0.5 分显示无痴呆或痴呆可疑;
6.BADL日常生活能力量表(barthel指数)显示无明显日常生活能力障碍;
7.GDS自评抑郁量表≤6分显示无抑郁;
8.可耐受3h的评估和干预;
9.自愿参加本研究并签署知情同意书。

Inclusion criteria

1. Patients meeting the core clinical diagnostic criteria of MCI;
2. Patients with age >= 50 years old and <= 85 years old are not limited in gender;
3. The subjects of Mini Mental State Scale: 18-19 for illiteracy, 21-22 for primary school, 25-27 for middle school and above;
4. Montreal Cognitive Assessment Scale score: low education (education years <= 12 years) 19-25 points, higher education (education years > 12 years) 19-26 points indicate mild abnormality.
5. Patients with clinical dementia rating scale score <= 0.5 showed no dementia or suspected dementia;
6. Patients with no obvious disorder of activities of daily living according to Barthel index;
7. Subjects with GDS <= 6 showed no depression;
8. Subjects who can tolerate 3 hours of assessment and intervention;
9. The subjects who voluntarily participated in this study and signed the informed consent.

排除标准:

1.局部皮肤感染 溃疡 瘢痕或对针刺过分敏感的患者;
2.严重的出血性疾病与凝血障碍疾病;
3.癫痫病史或癫痫发作史;一级亲属有癫痫病史;
4.身体内或头部有金属植入物(口腔科的除外);植入心脏起搏器 除颤器 人工耳蜗 药物泵;
5.未知原因的 对药物治疗无效的复发性头痛;
6.颅骨骨折和/或严重头部损伤;头部和/或脑部手术史;
7.严重心脏病和颅内压增高;
8.服用三环类抗抑郁药,精神安定药和其他降低癫痫发作阈值的药物;
9.有影响认知功能的其它疾病或病史;
10.有抑郁精神分裂等精神疾病;
11.妊娠期或哺乳期妇女。

Exclusion criteria:

1. Patients with local skin infection, ulcer scar or over sensitivity to acupuncture;
2. Patients with severe hemorrhagic diseases and coagulation disorders;
3. Patients with a history of epilepsy or seizures; first degree relatives have a history of epilepsy
4. Patients with metal implants in the body or head (except stomatology); patients with implanted pacemaker defibrillator and cochlear implant drug pump; patients with implanted pacemaker defibrillator and cochlear implant drug pump;
5. Patients with recurrent headache who have no response to drug treatment due to unknown reasons;
6. Patients with skull fracture and / or severe head injury; history of head and / or brain surgery;
7. Patients with severe heart disease and increased intracranial pressure;
8. Patients taking tricyclic antidepressants, antipsychotics and other drugs to reduce seizure threshold;
9. Patients with other diseases or history affecting cognitive function;
10. Patients with depression, schizophrenia and other mental diseases;
11. Pregnant or lactating women.

研究实施时间:

Study execute time:

From 2020-11-04 00:00:00 To 2021-12-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-11-04 00:00:00 To 2021-12-31 00:00:00

干预措施:

Interventions:

组别:

电针组

样本量:

10

Group:

EA

Sample size:

干预措施:

电针

干预措施代码:

Intervention:

EA

Intervention code:

组别:

真tACS+电针

样本量:

10

Group:

True tACS + EA

Sample size:

干预措施:

T真tACS+电针

干预措施代码:

Intervention:

True tACS + EA

Intervention code:

组别:

假tACS+电针

样本量:

10

Group:

Sham tACS+ EA

Sample size:

干预措施:

假tACS+电针

干预措施代码:

Intervention:

Sham tACS+ EA

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海中医药大学附属岳阳中西医结合医院 

单位级别:

三甲 

Institution
hospital:

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海中医药大学 

单位级别:

高校 

Institution
hospital:

Shanghai University of Traditional Chinese Medicine

Level of the institution:

University

测量指标:

Outcomes:

指标中文名:

脑电

指标类型:

主要指标

Outcome:

electroencephalography

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

眼动

指标类型:

次要指标

Outcome:

eye movement

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 50 years
最大 Max age 85 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用数字表法将符合纳入标准的患者随机分为A组、B组、C组

Randomization Procedure (please state who generates the random number sequence and by what method):

The patients who met the inclusion criteria are randomly divided into group A, group B and group C.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

对受试者施盲

Blinding:

Blind method for subjects.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

ResMan 临床试验公共管理平台, http://www.medresman.org.cn

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan, http://www.medresman.org.cn.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

保存纸质以及电子版本的数据

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data will be stored both in hard copy and in digital version as well.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2020-11-03 21:50:09